Neon Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$81.1M | −$78.7M | −$48.1M |
| Net income | −$79.8M | −$16.5M | −$9.5M |
| Total assets | $46.4M | $114.1M | $90.5M |
| Total liabilities | $17.0M | $12.8M | $8.8M |
| Equity | $29.4M | $101.2M | −$93.6M |
| EPS (diluted) | — | — | — |
| Shares out. | 28.3M | 28.3M | 3.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −271.2%
- Return on assets
- −172.0%
- Return on capital (ROCE)
- −225.6%
- Liabilities / assets
- 36.6%
- Debt / equity
- 0.58×
- Book value / share
- $1.04
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -24.81distress
- Accruals / assets
- −13.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMay 6, 2020
- Shareholder voteMay 5, 2020
- Other material eventApr 29, 2020
- Results of operationsMar 2, 2020
- Entered a material agreement · Other material eventJan 16, 2020
- Costs from exit or disposal · Director / officer change · Regulation FD disclosure · Other material eventNov 20, 2019
- Results of operationsNov 12, 2019
- Other material eventNov 8, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.